The mission of the Prostate Cancer Foundation is to find better treatments and a cure for recurrent prostate cancer.
As the Prostate Cancer Foundation nears its 15th year of seeking better treatments and an eventual cure for prostate cancer, we pledge to you – trusted partners, directors, donors, friends, survivors and families – that we will not rest until we accomplish the goal of ending death and suffering from prostate cancer.

We’re accelerating our timetable, harnessing every available resource and delivering needed funds to investigators on the brink of finding new discoveries to benefit men and their families.

Since 1993, generous donors like you have provided the means for the PCF to fund more than 1,400 investigators. We’ve received nearly 6,000 applications for our Competitive Awards Program that were submitted from scientific investigators at leading medical institutions in 43 countries. These investigators are on the frontline of research, working in concert to streamline their research approach and share best practices. And each year we bring together the world’s finest prostate cancer experts to collaborate on ideas, educate each other and energize the research field during the PCF Scientific Retreat.

All this activity is focused on the fact that one in six American men will be diagnosed with prostate cancer, the most-diagnosed non-skin cancer in the United States. In 2006 alone, more than 234,000 men received the unfortunate news. But there is cause for hope. When the PCF began in 1993, there were seven approved drugs for prostate cancer – today there are 13. Most importantly, even as the population of men at greatest risk has grown with the aging baby boom, there has been a 22% decrease in prostate cancer deaths. We want that number to be zero, and we can get there.

But we can’t do it alone. Just as we’re starting to turn the tide against prostate cancer, government funding for prostate cancer research is projected to decrease by 9% in 2007. We need your help to assist us in bridging the gap of resources. We need you to alert Washington that we will not tolerate a funding shortfall. And the timing is crucial. If we don’t increase the needed resources to learn how to prevent the disease, we will witness an estimated 37% increase in prostate cancer diagnoses by 2015 based on population trends. At the PCF, we’re aggressively accelerating our timetable to prevent this from happening.

In 2007, we’re confidently building on the solid foundation created by nearly five years of leadership under the PCF’s previous chief executive officer, Leslie D. Michelson. Thank you to our many generous friends and donors for their support throughout the years. We look forward to working with you to put the PCF out of business.

Michael Milken
Founder and Chairman

Jonathan W. Simons, MD
Chief Executive Officer
and President
David H. Koch Chair

Left to right: Leslie D. Michelson, Michael Milken and Jonathan W. Simons, MD
Prostate Cancer

Prostate cancer occurs when the cells of the prostate – a small, innocuous-looking gland that sits just below a man’s bladder inside his pelvis – begin to grow uncontrollably. It is the most common non-skin cancer in the United States, striking one in six men. In 2006 alone, more than 234,000 men were diagnosed with prostate cancer and more than 27,000 men died from the disease. Over the past decade, nearly 400,000 American men have been lost to this disease and nearly 2 million men are living with it.

Risk Factors

Although all the detailed mechanisms underlying the genetic damage in the prostate gland that leads to development of prostate cancer remain unknown, risk factors for prostate cancer are well understood and include age, race and family history.

- As men age, their risk of developing prostate cancer increases significantly. About 65% of all prostate cancers are diagnosed in men over the age of 65.
- Compared with Caucasian men, African American men are 60% more likely to develop prostate cancer, more likely to develop aggressive prostate cancer and twice as likely to die from the disease.
- Men with a first-degree relative – a father, a brother or even a son – with prostate cancer are twice as likely to develop the disease. The risk is even higher if the family members were diagnosed before age 60.

The Prostate Cancer Foundation is dedicated to harnessing and leveraging every available resource to find better treatments and a cure for recurrent prostate cancer.
Detection and Diagnosis

More than 95% of men who are diagnosed with and treated for early-stage disease remain disease-free after five years compared with only 35% of men who are diagnosed with late-stage disease.

The PSA (prostate-specific antigen) blood test and the digital rectal exam (DRE) are used to detect the presence of prostate cancer when no symptoms are present. An elevated PSA or an abnormal DRE can signal the need for a biopsy to examine the prostate cells and determine if they are cancerous.

The American Cancer Society recommends that both the PSA and DRE should be offered annually beginning at age 50 or earlier if there is a family history of prostate cancer.

The Team Approach to Prostate Cancer Management

The complexity of treating prostate cancer has yielded three different groups of prostate cancer specialists. Urologists, radiation oncologists and medical oncologists all play important roles in the management of men with prostate cancer and each group brings its own area of expertise to the treatment of men with this disease.

Yet these groups of physicians often work independently, potentially missing some opportunities to work as a team to maximize treatment options.

Over the past few years, the PCF has worked tirelessly to bring these groups together and to create a systemized team approach to prostate cancer management throughout the country. With this approach, men with prostate cancer can better benefit from the expertise of each type of specialist at every step of the way – learning about all available treatment options and choosing the treatment approach that’s right for them.
Since 1993, the Prostate Cancer Foundation has funded the work of more than 1,400 investigators — promoting innovative ideas in prostate cancer research and novel concepts in drug discovery and development.
Accomplishments in Science

Major programs instituted and implemented by the Prostate Cancer Foundation in 2006 helped researchers, physicians and patients stay up-to-date on the most recent research findings – and allowed the PCF to continue focusing its efforts on strategies to move the field forward.

Therapy Consortium
Thirteen years ago, when the PCF was founded, few institutions were focusing their efforts on establishing centers of excellence for prostate cancer research. With funding from the PCF, eight institutions across the country were able to establish rigorous prostate cancer research programs and become leaders in conducting prostate cancer clinical trials.

Since its inception, the PCF has collectively provided more than $23 million to the Therapy Consortium institutions, which include Cedars-Sinai Medical Center; Dana-Farber Cancer Institute; MD Anderson Cancer Center; Memorial Sloan-Kettering Cancer Center; The Johns Hopkins University; the University of California, San Francisco; the University of Michigan; and the University of Wisconsin.

The value of the PCF’s investment was demonstrated as nearly all were selected by the Department of Defense Prostate Cancer Research Program to receive three-year Clinical Consortium Awards, beginning in 2005. These awards are designed to help the nation’s leading research programs collaborate on clinical trials and further speed the development of new drugs and treatments for prostate cancer.

For a list of Therapy Consortium clinical investigators, see page 34.

Prostate Cancer Symposium
In 2006, nearly 1,500 practicing physicians, biopharmaceutical executives and government policy makers attended the Prostate Cancer Symposium, a three-day meeting focusing on issues to advance the standard of multidisciplinary care of men with prostate cancer. The program was co-sponsored by a partnership among the PCF, the American Society of Clinical Oncology, the American Society for Therapeutic Radiology and Oncology, and the Society of Urologic Oncology.

Consistent with the PCF’s efforts to promote a team approach to prostate cancer management, many presenters at the conference emphasized that important advances in patient care for prostate cancer come from coordinated efforts of all members of the healthcare team.
Competitive Awards Program

There is no shortage of innovative and creative ideas in prostate cancer research, only a shortage of resources to pursue them completely. Each year, the PCF’s Competitive Awards Program provides funding to investigators with unique and creative solutions to some of prostate cancer’s more difficult questions.

This focus on emerging scientific research has enabled the PCF to attract new talent to the prostate cancer research arena, and has played an important role in sparking novel ideas in drug discovery and development.

In 2006, the 63 physicians and scientists who represented the “best of the best” in prostate cancer research received funding through the Competitive Awards Program. Nearly $6.1 million was distributed, adding to the nearly $81 million distributed since the program’s inception in 1993.

For a complete list of institutions and investigators who have received funds from the Competitive Awards Program, see pages 30-33.

Countries that submitted applications for funding since inception

Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Cameroon, Canada, Chile, China, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, India, Ireland, Israel, Italy, Japan, Kazakhstan, Kenya, Kuwait, Mexico, Netherlands, New Zealand, Nigeria, Norway, Portugal, Puerto Rico, Russia, Scotland, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, United Kingdom, United States
Scientific Retreat
Each year, the PCF Scientific Retreat brings together scientific leaders from universities, governmental agencies and the biopharmaceutical industry to discuss challenges and solutions to the prostate cancer problem.

The 13th Annual Scientific Retreat in 2006 focused the attention of more than 200 investigators from five different countries on several major scientific areas of dramatic progress in the field and also some of the systemic obstacles that continue to impede success in prostate cancer research.

Sessions held during the Retreat highlighted critical areas of research currently underway at leading institutions around the world. Investigators presented landmark work in identifying molecular changes that play a key role in the development of prostate cancer and reviewed in detail laboratory studies being conducted on molecular targets and pathways known to play a role in prostate cancer progression. Most important, the discussions during all of the sessions revolved around how all of these findings might lead to the development of better treatments and a cure for prostate cancer.

Career Development Awards
Over the years, funding from the PCF has been an essential source of support for young physician-scientists who are starting their careers in prostate cancer research. In 2006, four outstanding junior faculty members at National Cancer Institute-designated Comprehensive Cancer Centers received Career Development Awards and were invited to present their work at the PCF Scientific Retreat.

The Career Development Program is named for Dr. Donald S. Coffey of The Johns Hopkins University, who is often referred to as one of the founding “fathers” of prostate cancer research. Dr. Coffey’s renowned emphasis on mentorship has set a standard for investigators across the country and is now being passed down to a new generation of prostate cancer investigators.

Aspen Summit
Capitalizing on its strong relationships with a wide range of individuals dedicated to fighting prostate cancer, the PCF brought together members of its Board of Directors, key prostate cancer investigators, donors and friends to explore how the PCF can bring about new and significant advances in prostate cancer research.

The Aspen Summit offered participants a new appreciation for the challenges in prostate cancer research today and highlighted the profound role that the PCF can play in accelerating progress toward finding better treatments and a cure for recurrent prostate cancer.
Commitment to Scientific Progress

The challenges that face the prostate cancer research community today are no less difficult to overcome than they were 13 years ago when the Prostate Cancer Foundation was started.

Prostate cancer remains a complex disease, the biology of which is difficult to understand. And its heterogeneous nature and slow, unpredictable and persistent growth patterns defy the standard treatment approaches used in other cancers. This is why continued efforts by dedicated PCF scientists to better understand how prostate cancer develops and spreads is so important.

Identifying New Strategic Opportunities for the PCF

In late 2005, the PCF launched an extensive six-month effort to gain insight from investigators in the field about what the PCF could do to help them move their research forward more rapidly.

The effort, led by the PCF Board of Directors and Bain & Company, focused on identifying new strategies that build upon the PCF’s unique capabilities to move the entire field forward. Most important, implementation of specific goals and milestones to measure these goals would allow the PCF to rapidly review its progress and adjust its strategies and investment of resources more wisely.

Senior research managers at major biopharmaceutical companies and the CEO of a major cancer center served as members of an Independent Expert Review Panel, which was tasked with evaluating the feedback received from the research community and submitting the recommended strategies to the Board of Directors. All of the participants, including those at Bain & Company, worked on a pro bono basis as a testament to their commitment to the PCF, and their recognition of the profound role that the PCF can play in the prostate cancer research arena.
At the conclusion of the review process, the PCF’s Board of Directors unanimously endorsed the recommendations to focus on the following three areas:

1. **Promoting Innovation in Prostate Cancer Research**  
   Over the years, the PCF has taken pride in encouraging and providing funding for investigators to explore new avenues of research. Unfortunately, funding for these proof-of-concept experiments is increasingly difficult to obtain. Thus, it is more important than ever that the PCF expand its role in promoting innovation in prostate cancer research. The PCF will grant multi-year awards consisting of greater amounts of money – enabling investigators to commit more time to science and less time to raising needed funds.

2. **Translating More Concepts and Compounds into Clinical Trials**  
   Because clinical trials evaluating new drugs for prostate cancer often take longer and require the enrollment of more patients than do trials for other cancers, it is not surprising that biopharmaceutical companies rarely make prostate cancer a high priority for early clinical trials. Yet, when proof-of-concept experiments and early-phase trials show that a drug is effective and safe, biopharmaceutical companies frequently decide to commit the necessary resources to the clinical development of new agents for prostate cancer.

   In continuous collaboration with investigators at major academic institutions, the PCF will drive efforts to identify and prioritize therapeutic compounds that should be tested in prostate cancer and move them rapidly through the first round of proof-of-concept and early-phase trials. With results from these studies in hand, the PCF will work with clinical trial consortia, biopharmaceutical companies and governmental agencies to ensure that these compounds are tested in men with prostate cancer.

3. **Identifying Better Markers of Disease Progression**  
   In prostate cancer, reliable markers of disease progression for making treatment decisions are urgently needed. Thus, clinical trials of new drugs typically run for five years or more to show a survival benefit and, on occasion, have closed early because the duration of the trial was too long to determine whether a clinical benefit would ultimately be seen.

   A new generation of biotechnological advances in the past few years now enables investigators to begin identifying markers that will signal – within weeks or months – whether the drug is working and reasonably predict long-term outcomes.

   Investigators working in this area recognize the need for collaboration to efficiently advance these markers into clinical trials and recognize the need for the PCF to lead this effort. Capitalizing on its unique, independent position in the research arena, the PCF will survey the landscape of progression markers for prostate cancer, begin to establish criteria for effective markers, facilitate collaboration among investigators and assist in overcoming institutional and regulatory obstacles.

**Advancing the Cure**

With the implementation of the PCF’s three initiatives, the landscape of prostate cancer research will dramatically shift toward increased investment, prioritization and enthusiasm for innovative solutions to the problem. All of this work is focused on the PCF’s central goal: to find better treatments and a cure for recurrent prostate cancer.
The Prostate Cancer Foundation partners with state and federal government agencies to harness available resources and support multi-institutional prostate cancer research programs across the country.

Representatives from state and federal government agencies who partner with the PCF.
Every year, the Prostate Cancer Foundation celebrates men and their families by using the Father’s Day holiday to honor men who are battling prostate cancer, educate those who are at risk of getting the disease and raise much-needed funds for research through targeted campaigns. In 2006, the PCF continued to work with long-term supporters Safeway and Major League Baseball and enlisted a new partner, Gillette and its Gillette Prostate Cancer Challenge program.

**Major League Baseball**
Since 1997, Major League Baseball (MLB) and the Major League Baseball Players Association have taken a swing against prostate cancer by teaming up with the PCF for the Home Run Challenge, raising more than $28 million for prostate cancer research. During the week of Father’s Day, MLB teams raise money from fans and sponsors who pledge money for each home run hit in 60 selected games.

In 2006, 153 home runs were hit and nearly $2.5 million was raised for prostate cancer research, with 42 home runs on Father’s Day alone. Baseball legends Reggie Jackson, Dennis Eckersley and Tommy Lasorda serve as Home Run Challenge Goodwill Ambassadors and made appearances across the country to raise awareness of prostate cancer and encourage people to make a pledge. In addition, FOX Networks, Horizon Media, Turner Broadcasting and Cablevision generously donated advertising space to publicize the program to potential donors.

**Safeway**
Celebrating six years of working with the PCF, Safeway and its family of premier food retailers raised a record $5.1 million for prostate cancer research from Memorial Day through July 4th. Led by Steve Burd, president and chief executive officer of Safeway, the company-wide campaign included point-of-purchase donation opportunities at more than 15,000 checkout stands in all 1,700 Safeway stores. This long-standing partnership has raised more than $17.6 million for prostate cancer investigators throughout the world.

**Gillette Prostate Cancer Challenge**
Joining the ranks of PCF supporters, in 2006 Gillette sponsored several elements of the PCF Home Run Challenge and helped conduct a Father’s Day national men’s health survey, which highlighted the lack of knowledge about prostate cancer and the critical role women can play in educating their loved ones.

Among many interesting findings, the PCF/Gillette Men’s Health Survey revealed that nearly three-quarters (72%) of men said they would be very likely to talk to their doctors about prostate cancer if asked by the women in their lives. Yet only half of women believe they have that kind of influence. The print and broadcast media coverage reached a potential combined audience of more than 25 million people, educating millions of Americans about the PCF, prostate cancer and the need for research funding.
### Athletes for a Cure

Hundreds of professional and amateur athletes across the country teamed with the Prostate Cancer Foundation to raise awareness about prostate cancer and to raise funds for research.

<table>
<thead>
<tr>
<th>Player</th>
<th>No. 450 - Total number of athletes participating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kevin Trock</td>
<td></td>
</tr>
<tr>
<td>Bill Bell</td>
<td></td>
</tr>
<tr>
<td>Petranek Fitness, CrossFit Los Angeles</td>
<td></td>
</tr>
</tbody>
</table>
A new program was launched in 2006 to assist athletes in endurance sports to increase awareness of prostate cancer and raise money for prostate cancer research.

Within months, 400 “athletes for a cure” ran, swam, biked and lifted weights to raise more than $350,000 – with the help of the Wade F. B. Thompson Matching Grant – for prostate cancer research.

A new website, www.athletesforacure.org, was also developed to create a home in the racing and fundraising community and provide athletes with multiple tools to set donation goals; upload photos, personal stories and race information; and send emails to their friends and family.

The program was carefully designed to give athletes the ability to raise money for prostate cancer research as part of any race event in which they are participating, although Athletes for a Cure worked closely with several designated events, including USA Triathlon, the Los Angeles Triathlon and CrossFit gym affiliates. In addition, several professional athletes proudly wore the Athletes for a Cure logo during their respective races, and dozens of current and new professional athletes are lined up to participate in 2007.
More than two million American men and their families are battling prostate cancer. It is a disease that affects countless families and communities which, in turn, touches everyone.

To help reach as many people as possible, in 2006 the Prostate Cancer Foundation continued to develop significant partnerships with corporations and organizations with the mutual goal of making a quantum leap forward in the fight against this disease. With their support, the PCF has raised more than $288 million, including $27 million in 2006 alone.

Examples of the PCF’s recent collaborations include:

HUGO BOSS

In 2006, HUGO BOSS, the maker of fine men’s and women’s clothing, hosted a private shopping event in nine of its retail stores across the country, including the Columbus Circle store in New York City and the Rodeo Drive store in Beverly Hills. Guests were able to view the BOSS Black, BOSS Orange and HUGO Fall/Winter 2006 collections and spin a wheel for a chance to win several prizes, including HUGO BOSS gift certificates. Fifteen percent of the evening’s proceeds benefited the PCF, and HUGO BOSS representatives also presented a $50,000 check to the PCF.

Since 2004, HUGO BOSS in-store events have raised nearly $150,000 to help find better treatments and a cure for prostate cancer.

Debbie Bohnett, Chief Operating Officer of the Prostate Cancer Foundation, accepted a $50,000 check from HUGO BOSS at the Columbus Circle store in New York City. HUGO BOSS representatives shown with her are, left to right, Bill Scott, Chief Operating Officer; Tony Lucia, Chief Executive Officer; and Vince Kavanaugh, Vice President of Retail Operations.
Giorgio Armani

Since 2005, Giorgio Armani, one of the world’s leading fashion and luxury purveyors, has teamed with the PCF to raise crucial funds for prostate cancer research.

Giorgio Armani, in partnership with Esquire, hosted a private shopping event in its Beverly Hills store in 2006. Guests were able to view the Men’s Made to Measure collection. Fifteen percent of the evening’s proceeds, along with items purchased for two weeks thereafter, benefited the PCF. In addition, proceeds from the ticket sales of a luxury raffle package were donated to the PCF.

NBA

For the first time, the PCF partnered with the National Basketball Association (NBA) and its NBA Cares initiative to offer special-edition NBA player wristbands. The different wristbands featured 18 stars and legends with team colors, player names, player signatures and uniform numbers.

Some of the current and former NBA players who participated in the program include LeBron James (Cleveland Cavaliers); Carmelo Anthony (Denver Nuggets); Kareem Abdul-Jabbar and Jerry West (Los Angeles Lakers); Shaquille O’Neal and Dwyane Wade (Miami Heat); Walt Frazier (New York Knicks); and Tim Duncan, George Gervin and Tony Parker (San Antonio Spurs).

The individual wristbands were sold at participating arenas, the NBA Store in New York City and online at NBAStore.com and www.prostatecancerfoundation.org.
Since inception of the Prostate Cancer Foundation, multiple prominent figures in politics, sports, film and television have proudly lent their time and support to help raise much-needed funds for prostate cancer research.
Arnies Army Battles Prostate Cancer
Since 2002, the PCF has worked with Arnies Army on one-day events built around a closest-to-the-pin contest on a par-3 hole. Banners, posters, pin flags and other collateral materials carry the program logo and all golfers are encouraged to join Arnies Army to help win the battle against prostate cancer. To date, Arnies Army has sponsored nearly 2,000 events, raising more than $1.3 million in the fight against prostate cancer.

Golf Digest Celebrity Invitational
_Golf Digest_ magazine hosted its second annual Golf Digest Celebrity Invitational at the Wilshire Country Club in Los Angeles to benefit the PCF. Event sponsors Ashworth, Cobra, Ketel One Vodka and Porsche helped raise nearly $200,000.

Hosted by Arnold Palmer and in support of Arnies Army Battles Prostate Cancer, the event featured musicians and celebrities from TV and film paired with amateur golfers. Twenty-five celebrities participated, including Richard Schiff, Kenny G. and Engelbert Humperdinck. Marty Rubino, a cancer survivor with a 25 handicap, made a hole in one and won a 2007 Porsche Cayenne.

In just two years, the Golf Digest Celebrity Invitational has raised more than $360,000 for prostate cancer research.

Lamkin Grips
Lamkin, the premier maker of golf club grips, partnered with the PCF for “Grips for Life,” a program created with Arnold Palmer that donates a portion of all proceeds from domestic Lamkin branded grip sales to help fund prostate cancer research. Lamkin has made a goal to raise at least $150,000 annually for prostate cancer research, and in 2006, the program surpassed the $300,000 mark in donations to the PCF.

Champions Tour for the Cure
Co-chaired by Arnold Palmer, Jim Colbert and Ray Floyd, Champions Tour for the Cure urges golf fans to pledge $1 or more for each birdie made by their favorite Champions Tour players throughout the season. Every birdie made between the MasterCard Championship in mid-January and the Charles Schwab Cup Championship in late October supports prostate cancer research. Since 1998, the Champions Tour for the Cure has raised more than $4.5 million to support prostate cancer research.
Fundraising Events

Prostate Cancer Foundation fundraising events seek to involve as many people as possible in the fight to find better treatments and a cure for prostate cancer. Supporters of the PCF come together to raise much-needed funds while also enjoying the camaraderie of others and updates about the PCF and its funding research efforts.

In 2006, PCF fundraising events included golf and tennis tournaments, formal dinners and other specialty programs. Highlights include:

A Night to Remember
Featuring gourmet food, delicious wines and an energetic live auction, the annual A Night to Remember event raised nearly $1 million for prostate cancer research. Hosted by Marvin Shanken, editor of Wine Spectator, the event was held at the Four Seasons Restaurant in New York City. Since inception, A Night to Remember has raised $6.7 million for the PCF.

Hamptons Pro–Am Tennis Invitational
David and Julia Koch welcomed the PCF back for a second year for a round-robin tennis tournament at the East Hampton Indoor & Outdoor Tennis Club in New York and a spectacular Pairings Party at their home. The weekend raised $1 million for the PCF’s research efforts.

An Evening at DANIEL
Guests of An Evening at DANIEL, held at the renowned French restaurant in New York City, rang in the 2006 holiday season by tasting award-winning Chef Daniel Boulud’s extraordinary cuisine and listening to the music of Tony Bennett and José Feliciano – a first-ever duet by these music legends. The first-time event raised more than $1.3 million for the PCF.
Carl H. Lindner Pro-Am Invitational Tennis Tournament

Hosted by Donald Trump at his Mar-a-Lago Club in Palm Beach, Florida, the round-robin tennis tournament drew a star-studded field of former tennis pros including Jared Palmer, David Adams and Brian MacPhie. Guests enjoyed the stand-up comedy of Jay Leno and the auction of a Metropolitan Choppers custom motorcycle for $110,000. In total, more than $700,000 was raised for prostate cancer research.

Wynn Las Vegas Invitational Weekend

Hosted by Steve and Elaine Wynn, the Wynn Las Vegas Invitational Weekend highlighted the best in dining, entertainment, the arts and other specially designed experiences. The two-day golf tournament featured several legends of NBA basketball, including Julius “Dr. J” Irving, Rick Barry and John Salley. Highlights of the weekend included a dance lesson from some of the stars of “Dancing with the Stars” and a special luncheon with designer Zac Posen. The event benefited the PCF and generated nearly $2 million for prostate cancer research.
<table>
<thead>
<tr>
<th>Player</th>
<th>Donors</th>
<th>No. 67,000 - Donors since inception</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Higger</td>
<td>David Higger and</td>
<td></td>
</tr>
<tr>
<td></td>
<td>his daughter, Ronni</td>
<td></td>
</tr>
<tr>
<td>David H.</td>
<td>David H. and Julia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Koch</td>
<td></td>
</tr>
<tr>
<td>Bob Each</td>
<td>Bob Each and family</td>
<td></td>
</tr>
<tr>
<td>Sherman</td>
<td>Sherman Miller and</td>
<td></td>
</tr>
<tr>
<td></td>
<td>family</td>
<td></td>
</tr>
<tr>
<td>Ed Silhan</td>
<td>Ed Silhan and family</td>
<td></td>
</tr>
</tbody>
</table>

The generous support of 67,000 donors has enabled the Prostate Cancer Foundation to support critical research — and every dollar raised has moved us closer to finding better treatments and a cure for recurrent prostate cancer.
In 2006, the Prostate Cancer Foundation nearly doubled its base from the previous year, expanding from 13,000 total donors in 2005 to 24,000 in 2006.

Across the nation, the PCF continues to educate and inform various audiences, including donors, prostate cancer survivors and their families, and the general public, about the PCF as an organization and its mission, prostate cancer statistics and the need for increased funding of prostate cancer research. These communications efforts included a quarterly newsletter, Focus, frequent website refreshes and updates, NewsPulse email news alerts, science updates and more.

In addition, amplified public relations efforts helped increase visibility, awareness and education about prostate cancer and the PCF. In 2006, the PCF secured more than 500 print, broadcast and online media placements, a 150% increase from the year before. Of many visible placements, the most noteworthy included The New York Times, AARP Magazine, Business Week, The Wall Street Journal, FORTUNE magazine, New York Post, Good Housekeeping, Sports Illustrated, Seventeen magazine, Reuters and Scripps Howard News Service.

Wade F. B. Thompson Matching Grant

For the second year in a row, PCF donors generously responded to a matching grant by Wade F. B. Thompson, a prostate cancer, melanoma and colon cancer survivor. Thompson, chairman, president and chief executive officer of Thor Industries, Inc., has dedicated himself to defeating cancer.

More than 8,500 PCF donors generously contributed $755,000 to the Wade F. B. Thompson Matching Grant, exceeding the $500,000 goal. Thompson matched the entire amount, resulting in a total of more than $1.5 million raised for prostate cancer research.

The 2006 Competitive Awards Program immediately benefited from the newly raised funds generated by the match, enabling the PCF to invest in many more promising research projects. Because of the extra funds available this year compared with last year, 17 more investigators received funds for their research projects in a diverse range of topic areas including genetics, biomarkers, immunotherapy and nutrition.
A Special Thank You

The Prostate Cancer Foundation would like to thank everyone who has supported us over the years. We gratefully acknowledge the following individuals, foundations, corporations and others who have given at least $5,000 since our inception.

**Founders**
($50,000,000 +)
Milken Family Foundation

**Founder’s Circle**
($2,000,000 – $49,999,999)
Anonymous (2)
David and Julia Koch
Thomas H. and Ann Tenenbaum Lee
Carl Lindner
Lowell Milken
Michael and Lori Milken
The News Corporation Foundation
Stewart and Lynda Resnick
Safeway, Inc.
Stephen and Elaine Wynn

**Leadership Circle**
($1,000,000 – $1,999,999)
Anonymous (5)
Abbott Laboratories
Aventis Pharmaceuticals, Inc.
Leon and Debra Black
Bristol-Myers Squibb Company
Jamie B. Coulter
Charles E. Dolan
William L. Edwards
Edward P. Evans Foundation
Andrew S. Grove
Sidney Kimmel
Bush Linsbraugh
The Lincy Foundation
Charles N. Mathewson Foundation
The Craig and Susan McCaw Foundation
Kerry Packer
Nelson and Claudia Peltz/Triarc Companies, Inc.
Ronald O. Perelman
PGA Tour Charities, Inc.
Julian H. Robertson, Jr.
William A. Schwartz
M. Shansky, Chairman
M. Shanken Communications, Inc.
Thomas Spiegel
Taste for Living
Ted and Dani Virtue
Wade F. B. Thompson
Charitable Foundation
Martin and Pamela Wygod

**Benefactors**
($500,000 – $999,999)
Anonymous (2)
Advance Magazine Group
Baume & Mercier Co.
The Bunker Foundation
Ronald W. Burkle
Winston H. Chen, PhD
Lawrence J. Ellison
Sue Gin
D. Wayne and Anne Gittinger
Golfers Against Cancer
The Greenspun Family Foundation
Kern Family Fund
Carol and Earle I. Mack
Richard N. Merkin, MD
Gordon E. Moore
Novartis Pharmaceuticals Corporation
Lewis and Pog Ranieri
Clifton S. Robbins Charitable Fund
Ellen and Richard V. Sandler, Esq.
Sanofi-Aventis
Jane and Terry Semel
David E. and Beth Kohlblew Shaw
Lester and Sue Smith Foundation
Edward M. Snider
Stuart Subotnick
Michael L. and Lynne Tarnopol
Stanley and Barbara Zax

**Patrons**
($250,000 – $499,999)
Anonymous (1)
Joseph and Annette Allen
Robert K. Barst
Brian and Kathleen Bean
James and Patricia Cayne
Stephen and Charialt Choochee
Conde Nast Publications, Inc.
L. John Doerr
David and Martha Ederer
Christian E. Ewens
The Gillette Company
Howard Gittis
Phillip and Lyn Goldstein
David and Sheryl Harkins Charitable Fund
Heinz Northwest America
Stephen and Tommie Habbert
The R.D. and Joan Dale Hubbard Foundation
Ray and Ghada Irani
Michael Jordan
Peter Karmanos, Jr.
Charles G. Koch
Herb and Natalie Kohler
C. Michael and Elizabeth Kojaian
Robert A. Kotick
Lamincon Corporation
F W McCarty Foundation
Richard Meisjies
Joy and Jerry Monkash Family Foundation
Bruce and Jeanne Nordstrom
Allen and Madeleine Paulsen
Sandra and Lawrence Post
Family Foundation
Gene and Marianne Salmon
Sanofi-Synthelabo
Mickey and Karen Shapiro
Melvin and Brem Simon
Charitable Foundation No.1
Paul and Elle Stephens
Sterling Equities
Warren and Jace Trepp
Clive T. Turner
Leslie L. Vadass
Varian Medical Systems, Inc.
Robert and Angela Voss
Dennis and Phyllis Washington
Gary and Karen Wincott

**Partners**
($100,000 – $249,999)
Anonymous (1)
William and Donna Acquavella
The G. Chris Andersen Family Foundation
Phillip and Nancy Anschutz
Ambassador George L. Argyros, Sr.
Arnie’s Army Battles Prostate Cancer
The Lynay Aymar Family Foundation
Charles and Tony Bagdasarian
Charles F. Baird, Jr.
Robert and Donna Baldwin
Charles and Michelle Becker
Marc R. Benioff
Braman Family Foundation
Eli & Edythe L. Broad Foundation
Gary S. Broad
John and Barbara Burns
August A. Busch, IV
California State Council ofLaborers
Ely R. Calloway
Wayne Calloway
CAO International, Inc.
Cendant Corporation
John and Jennifer Chalsty
Max C. Chapman, Jr.
David S. Collins
Concern Foundation
The Carole & Robert Daly Charitable Foundation
Thomas and Gun Dershak
James and Kristin Dolan
Dunwoody Senior Men’s Golf Association
Jeremy D. Eden
Don Engel
Ernst & Young LLP
William F. Farley
Ralph and Cynthia Finerman
M. Anthony and Anne Fisher
Sidney E. Frank
Richard S. Fuld, Jr.
Friendship Foundation, Inc.
The David Geffen Foundation
Richard and Phyllis Gelb
Gen-Probe Incorporated
Eric and Anne Gleacher
Thomas and Holly Gores
Greenbriar Golf Association
Orland S. Greene
Wayne and Janet Gretzky
Martin and Audrey Gross
Guggenheim Investment Management, LLC
Richard B. Handler
Joseph W. Harch
Thomas O. Hicks
Hilton Hotels Corporation
Leo Hindery, Jr.
Hugo Boss Fashions, Inc.
Jon and Karen Huntsman
Carl and Gail Icahn
Peter W. Jackson
Richard and Deborah Justice
Mel and Terry Karmazin
David Karpol
Solomon Kerzner
Michael and Jena King
Kissick Family Foundation
W. C. Klintworth
Knowledge Universe
Kovler Family Foundation
W. Howard and Mary Lester
Solomon and Rosie Lew
Peter B. Lewis
William and Phyllis Mack
Major League Baseball Charity, Inc.
Jeffrey A. Marcus
Leno and Peter May
Bruce R. and Jolene M. McCaw Fund
George A. Mealey
Robert A. Meister
MidOcean Partners
Arram Miller
S. Leslie and Barbara Mastrok
Kenneth and Julie Moelis
Moore Family Foundation
John and Rebecca Moores
Jay and Elaine Moorin,
Alain and Iris Schreiber,
and ProQuest Investments
Marc and Jane Nathanson
Nativity Jesuit Middle School
Linden Nelson
George and Sandra Nercross
John and Sally Nordstrom
OSI Pharmaceuticals
Palermo Ravich Family Foundation
Joel M. Pashcow
Rick Pitino
Bruce J. Raben
Rampage Trust
Summer and Paula Redstone
Brian and Patricia Reynolds
William A. Richardson
Leonard and Louise Riggio
Lee Rothman
Marc J. and Carolyn Rowan
Lewis and Rachael Rudin
Larry W. Ruvo
Haim and Cheryl Saban
San Francisco Giants
The John E. Scarpa Foundation
David and Janelle Shaffer
J. Gary and O.J. Shanasy Foundation
Silent Partners Inc.
Lori and Lisa Silverman
Eric and Susan Smidt
Shoes for Crews
David M. Solomon
Martin & Toni Sosnow Foundation
Alan G. Spero
Ary and Marcie Stein
Joseph and Diane Steinberg
1992 Charitable Trust
Ernest E. Stempel
The Stern Family Foundation
Roger and Susan Stone
Swing for the Cure
Marty Tenenbaum
Laurence and Billie Tisch
Torn and Diane Tuft
Van Van Auken
The Wagner Family Foundation
Raul and Vicki Walters
Wasserman, Corden, Casselman & Pearson, LLP
Will Weinstejn
Thomas and Emily Weisel
John F. Welch, Jr.
Jim and Kim Williams
San and Helen Zell
Selig Zases

**Associates**
($50,000 – $99,999)
Anonymous (4)
Robert W. Adler
Edward C. Alfred
Donors • continued

Bob Roberts
Richard and Barbara Rosenberg
Stan and Patti Rosenfeld
Round Hill Country Club
Andrew Ruotolo
Barry L. Rupp
Alvin and Marilyn Rush
Peter M. Sacerdote Foundation
David Sambol
The Mara and Ricky Sandler Foundation
Richard and Margaret Santulli
Richard Schmeekl
John H. Schnatter
Irving Schneider
Michael and Paola Schulhof
Bettl T. Setzer
David and Fela Shapell
William Shaw
Mace and Jan Siegel
David and Lynn Silfen
Fred L. Smith
Irwin and Lorri Spiegel
Fred and Sharon Stein
Steinberg Family Fund of, Inc.
Spencer Stokes
Burt and Mary Sugarman
Jim Tarlton
Mr. and Mrs. W. Thompson
James Tisch
Marc Uday
Peter Vagos
Michael and Laura Venerable
Linda J. Wachner
Charles F. Wagner
Samuel Walos
Ira Walker
Mr. and Mrs. Jay L. Wallberg
Stephen and Maura Walsh
Michael and Jill Weinstein
Stephen and Phyllis West
Christopher and Kristine Williams
H. L. Williams
Rick Winley
Don Zacharia

Supporters
($10,000 – $24,999)

Anonymous (2)
David and Kay Aaker
Paul Abecassis
S. Daniel Abraham
Abramson Family Foundation, Inc.
Joseph P. Adams, Jr.
Sheldon Adelson
Larry Atleto
Bruce and Elvin Ambler
Lee W. Ang
Judd Apatow
Michael F. Armstrong
Michael F. Ashby
Atlanta Braves Foundation, Inc.
Mark and Debbie Attanasio
Jerry Auerbach
Autism Speaks, Inc.
Abraham Azoulay
Dan Baldwin
Martin and Dorothy Bandier
Jeffrey C. and Lori Barabakow
Sol Barer
F. Harlan Batrus
William P. Beattie, Jr.
Richard J. Beattie
Warren Beatty and Annette Benning
Becker Family Fund of the Baltimore Community Foundation
Gary S. Becker

Michael Becker
Mitch Becker
Allen J. Beber
William J. Bell
Eric L. Berg
Jeff Berg
Anthony Bergamo, Esq.
Elliott H. Berger
Daniel G. Bergstein
David Berkossi
The Judy and Howard Berkowitz Foundation
Allen J. Bernstein
The Stanley & Joyce Black
Family Foundation
Joni Hirsch Blackman
Harvey Blau
Charles X. Block
Dennis Block
Bloomberg Financial Markets Commodities News
Burton Bornman
Albert R. Boscow
G. Michael Boswell
Reggie Bowserman
Steve Braverman
Bernard and Judy Briskin
Brooklyn Hospital Center
Harry I. Brown Foundation
Bryanston Group, Inc.
Kurt W. Butenhoff
Bernie F. Butler
Michael Butler
Canyon Partners
Cardean Learning
Michael Cardi
Liam Carlos
Johnny Carson
Donald and Nancy Carter
Edwin P. Carter
Marc L. Caenawage II
Cell Genesys, Inc.
Irwin Chafez
Linda Chen
Peter Chernin
Chubb Federal Insurance Company
Citigroup
The Clark Charitable Foundation
Coca-Cola Co.
Harold K. Cohen
Mitchell H. Cohen
Jim and Marcia Colbert
Commerence Bank, North, N.A.
Jimmy and Patti Connors
Nancy and James Cook
David and Courtnay Corletto
The David and Sheila Corstorphine Foundation
Jack B. Corwin
Ken Cory
Robert H. Cosgroff
Terry Cosgrove
Country Club of Roswell
Credit Suisse First Boston Corporation
Alberto Cribraro
Cuba Club
Chip Cashman
Theodore Czater
Cygnet Corporation
Dunby/Resnick Imperial
John Daly
Len and Barbara Darling Family Fund
Morton Davis
Marvin and Barbara Davis
Roger J. Davis
Michel De Beaumont
Joseph J. Dempsey
Donald J. Deutsch
Deutscher Bank

Terry Diamond
Dietz & Watson Foundation
Richard DiMeola
Don King Productions, Inc.
Donaldson, Lufkin & Jenrette
Carl Doumani
Milton H. Dresner Charitable Foundation
David H. Dreyfuss
Dunwoody Country Club
Alvin Dworman
Eastfield Realty, Inc.
Charles Edelstein
Stephen Einhorn
Steve Eisenman
David F. Enner
Roger A. Enrico
Mike Ensign
The Daniel J. Epstein Fund of the Jewish Community Foundation
Jeff Epstein
Evergreen Foundation
Jonathan D. Farkas
Federated Department Stores Foundation
Brad Feenstein
Robert M. Feld
James and Alise Ferency
Mike Ferry
The Diane and Elliot Feuerstein Fund
of the Jewish Community Foundation
Mark Finerman
Gerald B. Finneran
Jerome and Anne Fisher
Larry and Kathleen Fisher
Lester and Gwen Fisher
Richard Fisher
Joseph Flom
Florida Marlins
Steven T. Florio
Lyn Forester
Michael G. Foster, Jr.
Foxsports.com
Lionel Fraz
Fred C. Hutchinsen Cancer Research Center
Paul Fribourg
Joshua S. and Beth Friedman Family Fund
Stephen Friedman
Larry H. Friend
Peter Fudge
Jeffrey Furman
Frederick and Peggy Furr
Ronald H. Galowich
Michael and Lynn Garvey
General Nutrition Centers
Max Genger
Charles and Vivian Gillespie
The Honorable Rudolph W. Giuliani
Guilford and Diane Glazer
Alan and Marlene Gleicher
Seth Gluckenhaus
Colin Goldsmith, PhD
Bradley and Sunny Goldberg
Michael A. Goldberg
Andy Goldfarb
R. Anthony Goldman
Russell D. Goldsmith
Eric Goldstein
Michael Goldstein
The Golfworks
Lito Gomez
Bennett Goodman
The John R. & Kiendl Dauphinit Gordon Fund
Bryan Gordy, Jr.
Abraham D. Gosman
Fredric Gould
Laurence Graff
Mark Grant
Madison and Susan Graves
George D. Grayson
George L. Graziaeldo
Steven and Dorothea Green
Alan G. Greenberg
Gary and Sandra Grimes
Julie Grosskens
Michael S. Gross
Roger S. Haber
David and Leslie Hahn
Brian L. Halla
Clay W. Hamlin, III
James A. Harmon
Richard J. Harrington
Mel Harris
William B. Harrison, Jr.
Richard C. Hartnack
Albert and Irene Hartog
Richard J. Heckman
Andrew L. Heiskell
Bruce Heller
Jane Heller
Jerry Hennessy
Lawrence Herbert
Sam Herbst
Leon and Norma Hess
Andrew R. Heyer
Rick Hill
The Armin & Esther Hirsch Foundation
Dadie Finerman and Holly Ander
HLT Prostate Cancer Fund
H. S. Hoffman
Beth Hollfelder
Butch Holmes
Jane Holmes
Homonayous Homnapour
Home Box Office
Steven and Cathy Hooper
D. E. Brice Howe
Helme Huber
Gene Humphrey
Michael Hyatt
Royce Imhoff
International Financiers, Inc.
Invernir Associates LLC
Ironman Motivations
Jacks Broken Open
Herb W. Jacobs
Sheldon Jacobs
Ron Jacobson
Mr. and Mrs. Robert M. Jaffe
Leonard R. Jaskol
The JCT Foundation
Christopher M. Jeffries
Michael and Linda Jeselsohn
Clark A. Johnson
Allen N. Jones
Ellis B. Jones
The Joseph and Ida Foundation Inc.
Mitch Julis
John Kahrimoff Memorial Golf Tournament
Harold Sanford Kant, Esq.
Scott C. Kasen
Peter M. Kasch
Howard and Susan Kassel
David and Silvana Kay
Joshua and Josie Kazam
Dean C. Kehler
Gregory F. Kiernan
Brian King
Michael G. King, Jr.
Kirkland & Ellis Foundation
Joel Kirschenbaum
Daniel J. Kleinman
Calvin Klein
Michael and Patricia Klouwen
Harold and Shirley Kobliner
Jeff Kofman
KPMG, LLC
A. B. Kronegard
Mark Kurland
Herbert and Edyth Kure
Lachman Family Foundation
Jeffery & Nancy Lane Foundation, Inc.
Latham & Watkins
Leonard and Evelyn Lauder
William P. Lauder
Steve Lawrence and Elydie Goree
Norman Lear
Lederman Family Foundation
Don and Rita Lee
Laurence C. Leeds, Jr.
Richard S. LeFrak
Stephen R. Lebowitz
Alfred and Norma Lerner
Julius and Miriam Lesner
Frederick N. Levinger
Frances and Jack Levy Foundation
John S. Levy
Richard Levy
Loida N. Lewis
Robert Lietau
Mrs. Arthur Liman
Steven Lipman
Michael D. London
David B. Lowry
Rufus and Patricia Lummry
Robert G. Lux
Jerome D. Mack
Richard Mack
Macy's
John Magliocco
Peter A. Magowan
Mandaly Resort Group
Alan and Barbara Mandelbaum
Mandelbaum Foundation
Stuart Manheim, CPA
Mel Mann
Stephen J. Marcus
Mariners Care
Howard and Stacy Marks
Maverick Capital Foundation
Kenneth Marz
Larry Mazola
Michael and Kristy McChesney
Les G. McCraw, Jr.
John and Constance McGillicuddy
Thomas J. McKeen
Kara McKinley
J. P. McMann
James A. McRae
Medco Containment Co.
Keith Meister
Todd Meister
Prakash Mehrotra
Arnon Milchan
Lee S. Millstein
Larry A. Mizel
Robert Michael Mondavi
Charles K. Montfort
Eugene Monkash
David Moore
Pete Moore
Jerry Moss
Wayne Mueller
Donald R. Mullen
Peter Mullin
Bill Mundell
Mr. and Mrs. Warren V. Musser
Naples Drive for the Cure
The Nash Family Foundation
Menasche M. Nass
David Nazarian
Marlo Nealon
Rooney Nelson
New England Financial
Wayne and Kathleen Newton
NFL Charities
Perry Nisen, MD, PhD
Northern California District
Council of Laborers
Novacea, Inc.
Marlene Nusbaum
Oakland Athletics
Cindy K. Olson
Peter Busch Orthwein
Gregory J. and Mary V. Pacelli
Chuck Palombini
Marvin Parsons
Alan Patrocof
Norman J. Pattiz
Paul, Weiss, Rifkind, Wharton & Garrison, LLP
David Pecker
Clay and Elsie Pecorin
Gerry Pencer
Arthur Peron
Pensions 2000
Leonard C. Perham
Phillips-Heusen Foundation, Inc.
Phoenix Home Life Mutual Insurance Company
Albert and Jeanine Pirro
Michael A. Pitino
Mack Pogue
Carl and Eloise Pohlad Family Foundation
Steve Postma
Maury Povich and Connie Chung
Michael J. Price
Wayne Prin, Jr.
Jay Pritzker
Primedia International, Inc.
Ed W. Rabin
Sheri and Marc Rapaport Fund
Bruce Ratner
Michael Ratner
Randolph and Lindsey Read
John S. Reed
The Republic of Tea
W. Brent and Brenda Rice
Denise Rich
Robin Richards
James S. Riepe Family Foundation
Richard A. Rigg
Harold W. Ripp
Brian L. Roberts
Kern Roberts
Ralph J. Roberts
Thomas and Mary Alice Roberts
James D. Robinson, III
Rodney Strong Vineyards
Gerald Ronson
Allison Rosen
Fredric D. Rosen
Paul and Catherine Rosenberger
Betsy Ross
Byron Roth
James Rothstein
Michel Roux
Kenneth and Dina Russell
Edward B. Rust, Jr.
Donna Karan and Stephen Ruzow
Ronald Sachs
Steve Santak
Raymond and Helen Sandler
Richard Sandler
Michael Sandorffy
Sylvan Scheffer
Andrew Scheinman
David Schneider
Raymond D. Schoenhbaum
Lewis M. Schott
Ian Schrager
The Schulhof Family Foundation
Schultz Family Foundation
Marvin H. Schur
Charles and Helen Schwab
Alan D. Schwartz
Ted Schwartz
Schwartz, Kales Accountancy Corp.
Charles "Red" Scott
Russell Scott, Jr.
Tony Scott
Sebastian Vineyards, Inc.
Security Life Inc. Group
Henry Seiden
Dean G. Seidenberg
Martin Selig
Mike Shad
Michael Shapiro
Shearman & Sterling
Howard Shecter
Mark Shenkman
Robert D. Shippers
Boaz Shonfeld
Walter Shorestein
Stan Shuster
Stanley J. Sidel
Sidney Frank Importing Company, Inc.
Sanford C. Sigoloff
Eugene Silverman
Jay B. Silverman
Thomas M. Simms
Mark J. Simons
Ted Simpkins
Sires Society
Sanford Sirulnicky
John C. Sites
Charles B. Slack
Alan B. Silka
Lynn Smiliedge
John F. Smith, Jr.
Matthew and Tracy Smith
Orin Smith
Snyder Weiner Weltechek & Vogelstein
Marilyn Sobel
Bruce Sokoloff
Bob Solomon
Warren J. Specter
Allison Speer
Aron and Candy Spelling
Jerry Speyer
Lawrence Spira, MD
Joseph Stein
Jeffrey Steiner
Irvin Stern, Jr.
John F. Stier, Jr.
Carl Sternbaum
Michael Strauss
Steinlein Account of Fidelity Charitable Gift Fund
Lawrence Sheldon Stroll
Melanie Sturm
Marianne Suffin
Sanford and Charna Sugar
Sunbelt Beverage Company, LLC
Katharyn Swintek
Tag Associates, LLC
Roberta R. Tanenbaum
Jeremiah and Nonie Tarr
Fredricka Taubitz
Ian Ross Taylor
Robert Taylor
Douglas P. Teitelbaum
Anthony Teletto
Charles and Adele Thurber
Andrew H. and Ann Tisch
Daniel and Bonnie Tisch
Steven H. Tishman
Dennis A. Tito
John T. Toland
Bruce E. and Robbi S. Toll Foundation
Robert Toll
Joe and Alice Torre
Richard P. Torkylian, Sr.
Jesse I. Truig
Prabhakar Tripuraneni, MD, FACR
The Trump Organization
Tudor Investment Corporation
Valiquip Corporation
Karen van Nouhuys
Mary T. Venable
The Vons Companies Charitable Foundation, Inc.
Rosenmary Vrablic
Don Vultaggio
Shirleane A. Wainer
William and Claudia Walters
Charlene Wang
Kenneth Wang
William and Sharon Ward
Tom Watkins
Scott Watt
Robert F. Weiss
Melyn J. Weiss
Morris Weissman
Dr. Herbert A. Wertheim
Whittmore Family Foundation
Ralph and Wendy Whitworth
Arthur Winer
Henry Wilt
Andrew Wise
Alexander J. Witherill
Fred Wolf
Douglas J. Wood
C. Tal Wooten, Jr.
Young Presidents Organization, Los Angeles Chapter
Gerald Wernau
Louis G. Zachary, Jr.
Harriet Zaretsky
Jeffrey Dunston Zients
Roy Zuckerberg
Robert A. Zammo

Contributors
($5,000 – $9,999)
Anonymous (2)
Robert J. Abt
The Adler Family Foundation, Inc.
Advance Shared Services Center
AIC Management Group
Alvin R. Albe
Ellis J. Alden
R. Jack and Berulah Alexander
Donald and June Alfond
Lawrence B. Altecco
Allied Beverage Group, LLC
Arthur G. Altschul, Jr.
Ellsworth C. Altsvid, III
Richard W. Altvor
Ameripoint Foundation
John Angelo
Tom Armstrong
Phillip Avenian
Michael Ashkin
Sherrell Aston
Victoria K. Atkins
Aureon Laboratories, Inc.
Rick G. Ayer
Bacardi Limited
Jeffrey and Pamela Balton
Scott P. Barasch
Alexander E. Barkas and Lynda Wijick
Janis Balsevich
The Barrack Foundation
Tylor Barth
Michael J. Batza, Jr.
Charles T. Bauer
Ted Baum
Lee Beattie
Donors • continued

Cushman & Wakefield
Marion J. Davis, Jr.
Ed DeBartolo, Jr.
Paul Del Rossi
Delaware North Companies, Inc.
Delcal Enterprises, Inc.
Jerry Della Femina
Robert Dodson
Drexel University
Daniel A. Duc
Duch Family Fund of the Community Foundation
Raymond Duncan
Joseph J. Dvorak, Jr.
J. C. Earle Family Fund
Walter Eberstadt
Spencer E. Eccles
David B. Edelson
Maurits E. Edersheim
Anders B. Elek
Elmwood Country Club
EndoCare, Inc.
Mr. and Mrs. Engelberg
Robert Englander
Yan Erikk
Aaron R. Elman
Linda Evangelista
William F. Evans
Samer Farah, MD
Andrew Farkas
Michael S. Fawer
Dr. Jeffrey Feingold
Stanley M. Feingold
Irving Feintech
Frank and Victoria Ferritta
Gregory Fischbach
Richard B. Fisher
Stephen B. Fiverson
Karen A. Flann and Homer Schwartz
Dennis Flatt
Robert Forbes
Sam Forman
Gayle Devers Fortune
David Foster
Michael Frankel
Albert Fried, Jr.
Joel Friedland
Robert and Ann Fromer
Roy Furman
Tom W. Gamel
Howard Gamel
Lloyd Garver
Lucio and Marta Gasperina
Frank Gehry
Alan Gelband
Genentech, Inc.
Georgetown Tobacco & Pipe Stores, Inc.
S. William Gersten
Michael F. Gilligan, Jr.
Tom Giovannelli
David H. Glaser
Arthur M. Goldberg
Howard Goldenson
Steve A. Goldfarb
Dr. Kenneth N. Goldman
Bradford S. Goodwin
Richard Goodwin
Todd Goodwin
Jesse Gordon
S. William Gersten
Michael F. Gilligan, Jr.
Dr. Kenneth N. Goldman
Bradford S. Goodwin
Richard Goodwin
Greg Clark
Allen and Jill Choren
Clarium Capital Management, LLC
Greg Clark
John H. Cluster
Bert Cohen
Joseph M. Cohen
Richard D. Cohen
The Betsy and Alan Cohn Foundation, Inc.
Victor A. Cohn
William S. Comanor, PhD
Michelle A. Connelly
James C. Cook
Eline Terner Cooper
John Cooper, Jr.
Stephen A. Cooper, DMD, PhD
Peter Coors
The Copes Family Foundation
Fred Corrado
Marshall B. Coyne
Cresa Partners
Richard Crisman
Robert and Mary Ann Cross
Gregory Cumore
Cunningham Security Systems
Cushan
William and Evangeline Haarlow
Lynn M. Haff
Kerry and Kelly Hagen
John Haggard
Hall Dickler Kent Goldstein & Wood, LLP
Jesse Halpern
Fred Hameetman
Mark S. Handler
Mark S. Hanson
Martin Aaron Harman
Gilbert W. Harrison
Lauren M. Hartman
Kenneth and Kathryn Henderson
Thomas S. Henderson and Sally S.
Henderson Foundation
Arthur Hershaft
Michael B. Hershey
Edward and Gaye Hesron
David Hicks
Roderick Hills
Leslie Wohlman Himmel
Peter A. Hochfelder
Robert W. Hoke
Richard Scott Holländer
Vincent Horcasitas
Gerald Horowitz
John and Sandra Horvitz
Thomas J. Howa
Joe Howe
Mark Hughes
Wayne Huizenga
James Husband
George Hutchinson
Institute for Health & Productivity Management
Hale S. Irwin
The J.P. Morgan Chase Foundation
Jeremy Jacobs
Nathan P. Jacobs
Max Javit
Gordon W. Jenkins
Charles Jennings
Jewish Federation of Greater Phoenix
JFD / MJD Golf Open
James and Lorene Jimmerson
Alastair J. Johnston
Kaiser Permanente
Jay Kaiser
Thomas J. Kalinske
Bruce and Jeannie Kaminsky
The Kandell Fund
Walter Karahian
Stanley Katz
Stephen Katz
George Kaufman
Ivan Kaufman
Ronald S. Kaufman
Ian and Linda Kaufthal
Richard and Suzanne Kayne
Gershon Kest
Donald H. Keiter
Ken Roberts Company
Key Foundation
Kibble & Prentice
Katz, LLC
Lisa Kingsley
James W. Klein
Burton Koffman
Eugene Kohn
Osvaldo Kosta
Roger and Lorraine Kotch
Robert Kraft
Jules B. Kroll
Norman D. Kurtz
Laborers’ International Union -
El Monte Local 1082
Laborers’ International Union, Local 270
Laborers’ International Union
of North America - Local 300
LA- CO Industries, Inc.
Fred S. Lafer
Robert E. Lampe, Jr.
Ken Langston
Ira N. Langsam & Lillian Langsam
Philanthropic Fund
Richard Larner, MD
Martin and Sheila Lasky
Ronald Lauter
Lynn M. Leary
Frank Leanza
Ken Leese
Charles E. Leonard, III
Steve Leonard
Warner LeRoy
Margaret Lesher
John and Betty Levin
Neil Levine
Dan and Stacey Levitan
David Levy
Edward Lewis
The Liberal Do-Gooder Foundation
David Liebowitz
Sio Lindner
Samuel S. Lionel
Jeffrey and Susan Liss
The Litwin Foundation, Inc.
The Loe Productions, Inc.
The Arthur Loeb Foundation
John L. Loeb, Jr.
Shumur Lonsford
Bob Lorsch
Douglas and Nancy Lowe
Lynca Enterprises, Inc.
Harry Maddow
John Magnier
Anthony J. Magro
Brian A. Maki
Idelisse Malave
Jadd Malkin
Shareef Malnik
George J. Maloof
Bernard A. Marden
Morris Mark
Ken Martin
Kim Martindale
Elliott Masie
Norman and Joanne Matthews
Giacomo Mattoli
Caryn Mastner
Thomas and Musa Mayer
Marny McGo and Billy Davis
Richard E. McCready Foundation Fund of
the Baltimore Community Foundation
Liam E. McGee
John S. McVean
Laureston and Barbara McEllan
Don McNamara
Robert J. McNulty
Rolf Meijer-Wernar
Merrill Lynch & Company Foundation, Inc.
Merritt Management Corp.
The Morris and Helen Messing Foundation
David A. Miller
Laura and Michael Miller
Honorable Robert Joseph Miller
Peter H. Mills
Phillip S. Mittelman
Alan Mnuchin
Arthur and Patricia Modell
James J. Moglia
The Morris Animal Foundation
Robert Morris, MD
James M. Morris
Pacific Gas & Electric Company
Peter Morris
State Farm
Norman Morris
Carol Morris
James A. Moran
Steven Morris
Kenneth L. Morris
Charles Morris
John Morris
Stevie Nicks
John M. Moss
David Moss
Stephen Moss
David S. Moskowitz
John P. M. Mullin
John T. Mulcahy
Laura and David Mulcahy
The Mulcahy Foundation
John P. Mulcahy
Peter Mulcahy
Robert A. Mulcahy
Ronald P. Mulcahy
John P. Mulcahy
Peter Mulcahy
Robert A. Mulcahy
Ronald P. Mulcahy
John P. Mulcahy
The Prostate Cancer Foundation acknowledges the following biopharmaceutical companies that supported our work in 2006.

Donors

David Moore
Raymond Moore
Morongo Band of Mission Indians
William S. Morris, III
Morton's Restaurant Group
Judy Bardugo and Harve H. Mossawir, Jr.
Paul Motenko
Charles H. Mott
Joseph M. Murphy
Alan C. Myers
Douglas P. Nation
Lee S. Neibart
Craig T. Nelson
Mary-Rose Nelson
Nestlé Waters North America, Inc.
Blake Lee Neubauer, PhD
Shlom Neuman
Chuck Niccelle, MD
Niebaum-Coppola Estate Winery
James B. Nish
Douglas and Nancy Norberg
Greg Norman
Nush Foundation
Obermeyer Asset Management Company
James T. O'Brien
Morris Offit
John O'Hurley
Marvin Olshan
Sam Robson
Iber Rodriguez
Sig Rogich
Jeffrey Rosenthal
Stephen M. Ross
Goedhe Rother
Edward F. Rover
Army and Richard Ruben
Marciano A. Rubino
The Rachel and Lewis Rudin Family Foundation, Inc.
Denny Ryerson
Thomas L. Safran
Max Saltzer
Allan C. Sanders
Theodore and Alison Sands
Sandy Spring Bank
Patrick Savio
Saybrook Tax-Exempt Advisors, LLC
Al Scheid
Schmertz Company, Inc.
Allons J. Schmit
David M. Schoenthal
Marvin J. Schotland
Robert Schulman
Gerald M. Schuster
Governor Arnold Schwarzenegger and Mrs. Maria Shriver
Lisa White Schweitzer
Peter W. Schweitzer
Spencer and Jacqueline Segura
Dr. Michael E. Seiff
Richard M. Siegel
David M. Shaffer
Michael S. Shannon
Thomas J. Shannon, Jr.
Carl and Ruth Shaprio Family Foundation
Robert F. Shapiro
Thomas and Madeleine Sherak
Pam Shriver Fund of the Baltimore Community Foundation
Herbert J. Siegel
William Siegel
Van Skilling
Joel E. Smilow
Gordon Smith
Jeff N. Smith
Arnold Snider
Dick Simon
Mimi Simoneaux
James D. Sinegal
Van Skilling
Joel E. Smilow
Gordon Smith
Jeff N. Smith
Arnold Snider
Steve Snyder
James Soules
Southern Company Services, Inc.
Larry Spicaufsky
Richard and Ellie Sprague
Frank P. Stagen
Starbucks Coffee Company
John Stark
Steven E. Stern
The Stone Family Fund
Bonnie and Tom Strauss
Chris Stuhmier
Mary M. Sullivan
Dennis A. Suskind
Don Swirnow
S. Jerome and Judith Tamkin
Rica F. Tarnoff
Janie C. Tater
Stanley G. Tate
Walter D. Tease
Vincent Tew
Chuck B. Thornton, Jr.
The Laura Steinberg Tisch Foundation, Inc.
Tom Tisch
TJH
Stanley S. Tostman, Jr.
Cecily Truett
Mark Truett
Jeffrey H. Tucker
Turner Broadcasting System, Inc.
Alfred Tyler II
UBS AG
Peter V. Ueberroth
William D. Utten
United Jewish Foundation of Metropolitan Detroit
Tom Utterman
Michael J. Urriri
Neil G. Van Luan
Baud F. Vasiliou
The Daniel Veloric Foundation
Velos Medical Informatics, Inc.
Mary E. Venable
Benjamin Wade
Robert and Judy Walker
David E. Walters
John Walter
Jack L. Warner
Roger Weber
Raymond J. Weis
Robert Weiss
Jay Weitzman
Miles D. White
Jeffrey S. Wilks
Gary L. Wilson
Daniel P. Wimsatt
Moira Wlofsky
Rodney A. Wray
Bud Yorkin
Young Presidents Organization
Rebel Chapter
Stam Zicklin
Ron Zimmerman

The Prostate Cancer Foundation acknowledges the following biopharmaceutical companies that supported our work in 2006.

Partnering with the medical industry enables the Prostate Cancer Foundation to play an important role not only in the early discovery of innovative research ideas but also in the development of new therapeutics that can help men with prostate cancer live longer and better lives.
The Prostate Cancer Foundation’s Competitive Awards Program supports innovative, early-stage prostate cancer research projects. The following institutions and researchers have received funds from this program.

**Research Awards**

<table>
<thead>
<tr>
<th>Institution</th>
<th>Funding</th>
</tr>
</thead>
<tbody>
<tr>
<td>Albert Einstein College of Medicine</td>
<td>$75,000</td>
</tr>
<tr>
<td>Nicole B. Schreiber-Agus, PhD</td>
<td></td>
</tr>
<tr>
<td>Assaf Harofe Medical Center (Israel)</td>
<td>$100,000</td>
</tr>
<tr>
<td>Amnon Zisman, MD</td>
<td></td>
</tr>
<tr>
<td>Bar-Ilan University (Israel)</td>
<td>$225,000</td>
</tr>
<tr>
<td>Shlomo Grossman, PhD</td>
<td></td>
</tr>
<tr>
<td>Uri Nir, PhD</td>
<td></td>
</tr>
<tr>
<td>Baylor University</td>
<td>$3,855,000</td>
</tr>
<tr>
<td>Jacques Banchereau, PhD</td>
<td></td>
</tr>
<tr>
<td>Baylor College of Medicine</td>
<td></td>
</tr>
<tr>
<td>Norman M. Greenberg, PhD</td>
<td></td>
</tr>
<tr>
<td>Naijie Jing, PhD</td>
<td></td>
</tr>
<tr>
<td>Dov Kadmon, MD</td>
<td></td>
</tr>
<tr>
<td>Paula Kaplan-Lefko, PhD</td>
<td></td>
</tr>
<tr>
<td>Michael Kattan, PhD</td>
<td></td>
</tr>
<tr>
<td>Dolores J. Lamb, PhD</td>
<td></td>
</tr>
<tr>
<td>Bert W. O'Malley, MD</td>
<td></td>
</tr>
<tr>
<td>David R. Rowley, PhD</td>
<td></td>
</tr>
<tr>
<td>Peter T. Scardino, MD</td>
<td></td>
</tr>
<tr>
<td>Timothy C. Thompson, PhD</td>
<td></td>
</tr>
<tr>
<td>Ming-Jer Tsai, PhD</td>
<td></td>
</tr>
<tr>
<td>Nancy L. Weigel, PhD</td>
<td></td>
</tr>
<tr>
<td>Ming Zhang, PhD</td>
<td></td>
</tr>
<tr>
<td>Ben-Gurion University of the Negev (Israel)</td>
<td>$325,000</td>
</tr>
<tr>
<td>Ron N. Apte, PhD</td>
<td></td>
</tr>
<tr>
<td>Joseph Levy, PhD</td>
<td></td>
</tr>
<tr>
<td>Angel Porgador, PhD</td>
<td></td>
</tr>
<tr>
<td>Shraga Segal, PhD</td>
<td></td>
</tr>
<tr>
<td>Beth Israel Deaconess Medical Center</td>
<td>$560,000</td>
</tr>
<tr>
<td>Lewis C. Cantley, PhD</td>
<td></td>
</tr>
<tr>
<td>Mark A. Exley, MSC, PhD</td>
<td></td>
</tr>
<tr>
<td>John V. Fragoni, MD, PhD</td>
<td></td>
</tr>
<tr>
<td>Sandra M. Gaston, PhD</td>
<td></td>
</tr>
<tr>
<td>Xiaosong Gu, PhD</td>
<td></td>
</tr>
<tr>
<td>Richard Junghans, MD, PhD</td>
<td></td>
</tr>
<tr>
<td>Towa A. Libermann, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>Massimo Loda, MD</td>
<td></td>
</tr>
<tr>
<td>Jan E. Schnitzer, MD</td>
<td></td>
</tr>
<tr>
<td>Brandeis University</td>
<td>$250,000</td>
</tr>
<tr>
<td>Lizbeth Hedstrom, PhD</td>
<td></td>
</tr>
<tr>
<td>Gregory A. Petsko, PhD</td>
<td></td>
</tr>
<tr>
<td>Brigham and Women’s Hospital</td>
<td>$690,000</td>
</tr>
<tr>
<td>Anthony V. D’Amico, MD, PhD</td>
<td></td>
</tr>
<tr>
<td>Francesca Demichelis, MSC, PhD</td>
<td></td>
</tr>
<tr>
<td>Phillip G. Febbo, MD</td>
<td></td>
</tr>
<tr>
<td>James W. Fett, PhD</td>
<td></td>
</tr>
<tr>
<td>Joshua LaBaer, MD, PhD</td>
<td></td>
</tr>
<tr>
<td>Kevin R. Loughlin, MD</td>
<td></td>
</tr>
<tr>
<td>Jing Ma, MD, PhD</td>
<td></td>
</tr>
<tr>
<td>Karen A. Olson, PhD</td>
<td></td>
</tr>
<tr>
<td>Jeffrey L. Sklar, MD</td>
<td></td>
</tr>
<tr>
<td>British Columbia</td>
<td></td>
</tr>
<tr>
<td>Cancer Agency</td>
<td>$100,000</td>
</tr>
<tr>
<td>Yuzhuo Wang, PhD</td>
<td></td>
</tr>
<tr>
<td>Burnham Institute</td>
<td>$1,888,666</td>
</tr>
<tr>
<td>Wadh Arap, MD, PhD</td>
<td></td>
</tr>
<tr>
<td>Nuria E. Asse-Munt, PhD</td>
<td></td>
</tr>
<tr>
<td>Kathryn R. Ely, PhD</td>
<td></td>
</tr>
<tr>
<td>John C. Reed, MD, PhD</td>
<td></td>
</tr>
<tr>
<td>Erkki I. Ruoslahti, MD</td>
<td></td>
</tr>
<tr>
<td>California Institute of Technology</td>
<td>$450,000</td>
</tr>
<tr>
<td>Raymond J. Deshaies, PhD</td>
<td></td>
</tr>
<tr>
<td>Huftao Guo, PhD</td>
<td></td>
</tr>
<tr>
<td>Alexander J. Varshavsky, PhD</td>
<td></td>
</tr>
<tr>
<td>California Pacific Medical Center</td>
<td>$100,000</td>
</tr>
<tr>
<td>Robert J. Debs, MD</td>
<td></td>
</tr>
<tr>
<td>Cancer Institute of New Jersey</td>
<td>$75,000</td>
</tr>
<tr>
<td>Robert S. DiPaola, MD</td>
<td></td>
</tr>
<tr>
<td>Cantonal Hospital St. Gall (Switzerland)</td>
<td>$75,000</td>
</tr>
<tr>
<td>Marcus Groettrup, PhD</td>
<td></td>
</tr>
<tr>
<td>Case Western Reserve University</td>
<td>$350,000</td>
</tr>
<tr>
<td>Sanford Markowitz, MD, PhD</td>
<td></td>
</tr>
<tr>
<td>Bingcheng Wang, PhD</td>
<td></td>
</tr>
<tr>
<td>Cedars–Sinai Medical Center</td>
<td>$3,556,640</td>
</tr>
<tr>
<td>David B. Agus, MD</td>
<td></td>
</tr>
<tr>
<td>H. Phillip Koehler, MD</td>
<td></td>
</tr>
<tr>
<td>Isett Laux, MD</td>
<td></td>
</tr>
<tr>
<td>Children’s Hospital Boston</td>
<td>$900,000</td>
</tr>
<tr>
<td>Judah Folkman, MD</td>
<td></td>
</tr>
<tr>
<td>Michael Klagsburn, PhD</td>
<td></td>
</tr>
<tr>
<td>Calvin I. Kuo, MD</td>
<td></td>
</tr>
<tr>
<td>Marsha A. Moses, PhD</td>
<td></td>
</tr>
<tr>
<td>Richard C. Mulligan, PhD</td>
<td></td>
</tr>
<tr>
<td>Bruce R. Zetter, PhD</td>
<td></td>
</tr>
<tr>
<td>Cleveland Clinic Foundation</td>
<td>$250,000</td>
</tr>
<tr>
<td>Katerina Gurova, PhD</td>
<td></td>
</tr>
<tr>
<td>Edward Pow, PhD</td>
<td></td>
</tr>
<tr>
<td>Robert H. Silverman, PhD</td>
<td></td>
</tr>
<tr>
<td>Cold Spring Harbor Laboratory</td>
<td>$100,000</td>
</tr>
<tr>
<td>Robert Lucito, PhD</td>
<td></td>
</tr>
<tr>
<td>Columbia University</td>
<td>$2,229,500</td>
</tr>
<tr>
<td>Allen Pavilion Presbyterian Hospital</td>
<td></td>
</tr>
<tr>
<td>Carl A. Olsson, MD</td>
<td></td>
</tr>
<tr>
<td>Atchley Pavilion</td>
<td></td>
</tr>
<tr>
<td>Ralph Buttyan, PhD</td>
<td></td>
</tr>
<tr>
<td>College of Physicians and Surgeons</td>
<td></td>
</tr>
<tr>
<td>Paul B. Fisher, PhD</td>
<td></td>
</tr>
<tr>
<td>Aaron E. Katz, MD</td>
<td></td>
</tr>
<tr>
<td>Nickolas Papadopoulos, PhD</td>
<td></td>
</tr>
<tr>
<td>Columbia Presbyterian Medical Center</td>
<td></td>
</tr>
<tr>
<td>Edward P. Gelmann, MD</td>
<td></td>
</tr>
<tr>
<td>Daniel Petrylak, MD</td>
<td></td>
</tr>
<tr>
<td>Cornell University</td>
<td>$4,199,325</td>
</tr>
<tr>
<td>Beatrice S. Knudsen, MD</td>
<td></td>
</tr>
<tr>
<td>David M. Nanus, MD</td>
<td></td>
</tr>
<tr>
<td>New York Presbyterian Hospital</td>
<td></td>
</tr>
<tr>
<td>Neil H. Bander, MD</td>
<td></td>
</tr>
<tr>
<td>Ashutosh K. Tewari, MD</td>
<td></td>
</tr>
<tr>
<td>Dana–Farber Cancer Institute</td>
<td>$6,085,000</td>
</tr>
<tr>
<td>Ranaa Berger, MD, PhD</td>
<td></td>
</tr>
<tr>
<td>Myles A. Brown, MD</td>
<td></td>
</tr>
<tr>
<td>Harvey Cantor, MD</td>
<td></td>
</tr>
<tr>
<td>Diego Castrillon, MD, PhD</td>
<td></td>
</tr>
<tr>
<td>Lan Bo Chen, PhD</td>
<td></td>
</tr>
<tr>
<td>Ronald A. DePinho, MD</td>
<td></td>
</tr>
<tr>
<td>Glenn Dronoff, MD</td>
<td></td>
</tr>
<tr>
<td>Phillip G. Febbo, MD</td>
<td></td>
</tr>
<tr>
<td>Levi A. Garraway, MD, PhD</td>
<td></td>
</tr>
<tr>
<td>Prostate Cancer Foundation</td>
<td></td>
</tr>
<tr>
<td>The Prostate Cancer Foundation has played an important role in helping to establish and support nearly 150 robust prostate cancer research programs at institutions in the United States and worldwide — nearly 10 times the number of programs in place when the PCF was founded in 1993.</td>
<td></td>
</tr>
<tr>
<td>Institution</td>
<td>Amount</td>
</tr>
<tr>
<td>-------------</td>
<td>--------</td>
</tr>
<tr>
<td>Harvard University</td>
<td>$250,000</td>
</tr>
<tr>
<td>Harvard Medical School</td>
<td>$2,050,000</td>
</tr>
<tr>
<td>Hebrew University (Israel)</td>
<td>$1,200,000</td>
</tr>
<tr>
<td>Indiana University</td>
<td>$300,000</td>
</tr>
<tr>
<td>Institute for Systems Biology</td>
<td>$500,000</td>
</tr>
<tr>
<td>John Wayne Cancer Institute</td>
<td>$50,000</td>
</tr>
<tr>
<td>Johns Hopkins University</td>
<td>$15,871,867</td>
</tr>
<tr>
<td>Kentucky Institute for Biomedical Research</td>
<td>$500,000</td>
</tr>
<tr>
<td>Loyola University Medical Center</td>
<td>$200,000</td>
</tr>
<tr>
<td>Massachusetts Institute of Technology</td>
<td>$1,205,000</td>
</tr>
<tr>
<td>Mayo Clinic</td>
<td>$500,000</td>
</tr>
<tr>
<td>Memorial Sloan–Kettering Cancer Center</td>
<td>$18,903,272</td>
</tr>
</tbody>
</table>

Awardees were performing research at the listed institution at the time funds were granted.
**Research Awards • continued**

**Oregon Health Sciences University**  
$100,000  
Ron G. Rosenfeld, MD

**Preventive Medicine Research Institute**  
$500,000  
Dean Ornish, MD

**Rabin Medical Center (Israel)**  
$50,000  
Avishay Sella, MD

**Rockefeller University**  
$500,000  
Robert G. Roeder, PhD

**Strang Cancer Research Laboratory**  
Martin Lipkin, MD

**Roger Williams Medical Center**  
$225,000  
Richard P. Junghans, MD, PhD

**Salk Institute for Biological Studies**  
$760,500  
Ronald M. Evans, PhD

**San Diego Cancer Research**  
$75,000  
R. Michael Williams, MD, PhD

**Scripps Research Institute**  
$975,000  
Prabhakar Tripuraneni, MD

**Sheba Medical Center (Israel)**  
$150,000  
Gideon Rechavi, MD, PhD

**Sidney Kimmel Cancer Center**  
$100,000  
Michael McClelland, PhD

**Skirball Institute of Biomedical Medicine**  
$100,000  
Ruben A. Abagyan, PhD

**St. Louis University**  
$75,000  
William S.M. Wold, PhD

**Stanford University**  
$1,500,000  
Gerald R. Crabtree, MD  
David Feldman, MD  
Calvin J. Kuo, MD, PhD  
John E. McNeal, MD  
Donna M. Peetl, PhD  
Thomas A. Stamey, MD

**State University of New York**  
$112,500  
Downstate Medical School  
Jack Mydlo, MD

**Stony Brook**  
Victor I. Romanov, PhD

**Technion, Israel Institute of Technology (Israel)**  
$950,000  
Ami Aronheim, PhD  
Aaron Giechanover, MD, DSc  
Fuad Fares, DSc  
Ehud Keinan, PhD  
Gera Neufeld, PhD  
Israel Vlodavsky, PhD

**Tel-Aviv University (Israel)**  
$400,000  
Zvi Fishelson, PhD  
Sara Lavi, PhD

**UCLA**  
Ruben A. Abagyan, PhD

**Sourasky Medical Center**  
Ben-Zion Katz, MD  
Avi Orr-Urtreger, MD, PhD

**Thomas Jefferson University**  
$125,000  
Michael J. Mastrangelo, MD  
Albert J. Wong, MD

**Tulane University**  
$500,000  
Andrew V. Schally, MD, PhD

**University Hospital, Nijmegen (Netherlands)**  
$275,000  
Marion J.G. Bussmakers, PhD

**University of Alabama, Birmingham**  
$200,000  
David T. Curied, MD  
Richard D. Lopez, MD

**University of Arizona**  
$100,000  
Leslie Gunatilaka, PhD  
Mark W. Kunkel, PhD

**University of Basel (Switzerland)**  
$75,000  
Lukas Rubendorf, MD

**University of Bern (Switzerland)**  
$100,000  
George N. Thalmann, MD

**University of British Columbia**  
$200,000  
Martin E. Gleave, MD

**University of California, San Francisco**  
$8,685,898  
Jeffrey Arbeot, MD  
Allan Balmain, PhD  
Elizabeth Blackburn, PhD  
Robert H. Blalock, MD, PhD  
Robert A. Bok, MD, PhD  
Peter R. Carroll, MD  
June M. Chan, ScD  
Collin Collins, PhD  
Heike E. Daldrop-Lask, MD, PhD  
Marc I. Diamond, MD  
Robert J. Fletterick, PhD  
Mark W. Frohlich, MD  
Rodney Guy, PhD  
Douglas Hanahan, PhD  
Ronald H. Jensen, PhD  
John Kurhanewicz, PhD  
James D. Marks, MD, PhD  
Dean Ornish, MD  
Timothy P. Quinn, MD  
Mack Roach, III, MD  
Eric J. Small, MD  
Thea Tistly, PhD  
Paul Webb, PhD

**University of California, Santa Barbara**  
$100,000  
Dulal Panda, PhD

**University of Chicago**  
$492,900  
Douglas K. Bishop, PhD  
Carrie W. Rinker-Schaeffer, PhD  
Mitchell H. Socoloff, PhD

**Ben May Institute for Cancer Research**  
Shutsung Liao, PhD

**University of Colorado**  
$730,000  
L. Michael Glode, MD  
William E. Huffer, MD  
Andrew S. Kraft, MD  
Gary J. Miller, MD, PhD

**University of Connecticut**  
$147,603  
Linda H. Shapiro, PhD  
Pramod Srivastava, PhD

**University of Edinburgh (Scotland)**  
$75,000  
Fouad K. Habib, PhD

**University of Helsinki (Finland)**  
$200,000  
Institute of Biomedicine  
Olli A. Janne, MD, PhD

**University of Illinois**  
$150,000  
Nissum Hay, PhD

**University of Illinois, Urbana–Champaign**  
Jianjun Cheng, PhD

Awardees were performing research at the listed institution at the time funds were granted.
University of Innsbruck (Austria)  
$103,000  
Zoran Culig, MD

University of Iowa  
$175,000  
Michael D. Henry, PhD  
George Weiner, MD

University of Kentucky  
$100,000  
Vivek M. Rangnekar, PhD

University of Louisville  
$100,000  
LaCreis R. Kidd, PhD, MPH

University of Maryland  
$300,000  
Natasha Kyprianou, PhD  
Yun Qiu, PhD  
Vivek M. Rangnekar, PhD  
George C. Prendergast, PhD

University of Massachusetts  
$425,000  
Robert E. Carraway, PhD  
Michael R. Green, MD, PhD  
Shuk-Mei Ho, PhD  
Shoukat Dedhar, PhD

University of Michigan  
$4,624,935  
Mani Menon, MD  
Shuk-Mei Ho, PhD  
Michael R. Green, MD, PhD  
Robert E. Carraway, PhD  
Janet Stanford, MD  
Jeffrey Gingrich, MD  
Donald L. Trump, MD

University of Pittsburgh  
$2,623,900  
Michael J. Becich, MD, PhD  
Barbara A. Foster, PhD  
John Gilbertson, MD  
Susan L. Greenspan, MD  
Candace S. Johnson, PhD  
Joel B. Nelson, PhD  
Denise S. O'Keefe, PhD  
Beth R. Pflug, PhD  
Uzma S. Shah, PhD  
Donald L. Trump, MD  
Janey Whalen, PhD

University of Regensburg  
(Germany)  
$99,760  
Christoph A. Klein, MD

University of Rochester  
$500,000  
Chawnsang Chang, PhD  
Edward Messing, MD  
Ganesh S. Palapattu, MD

University of Southern California  
$589,282  
Ganesh S. Palapattu, MD

University of Tampere  
(Finland)  
$300,000  
Tapio Visakorpi, MD, PhD

University of Tennesseee  
$150,000  
Jeffrey Gingrich, MD

University of Texas  
$14,728,213  
Health Science Center at San Antonio  
Sudan Padalecki, PhD  
MD Anderson Cancer Center  
Wadih Arap, MD, PhD  
Denai Daliani, MD  
John DiGiovanni, PhD  
Isaiah J. Fidler, DVM., PhD  
Sue-Hwa Lin, PhD  
Christopher J. Logothetis, MD  
David J. McConkey, PhD  
Timothy J. McDonnell, MD, PhD  
Douglas G. McNeel, MD, PhD  
George Wilding, PhD  
Donald T. Witiak, PhD

University of Wisconsin  
$4,164,580  
David A. Boothman, PhD  
Wade Bushman, MD, PhD  
Chawnsang Chang, PhD  
David F. Jarrard, MD  
Douglas G. McNeel, MD, PhD  
George Wilding, PhD  
Donald T. Witiak, PhD

University of Washington  
$4,361,342  
Mitchell H. Sokoloff, MD  
Fraydoon Rastinejad, PhD

Wayne State University  
$350,000  
Michael L. Cher, MD  
Kenneth V. Horn, PhD

Weizmann Institute of Science  
(Israel)  
$1,949,650  
Avri Ben-Ze’ev, PhD  
Hadasa Degani, PhD  
Zelig Eshhar, PhD  
Benjamin Geiger, PhD  
Yitzhak Koch, PhD  
Rony Seger, PhD  
Yechiel Shai, PhD  
Yosef Shaul, PhD  
David Wallach, PhD  
Yosef Yarden, PhD  
Yehiel Zick, PhD

Wake Forest University  
$65,000  
Purnima Dubey, PhD

Walter Reed Army Medical Center  
$50,000  
David G. McLeod, MD, JD

Washington University  
$3,399,166  
William J. Catalona, MD  
Mark L. Day, PhD

Wistar Institute  
$100,000  
LaCreis R. Kidd, PhD, MPH  
Mike A. Parry, PhD  
Mark A. Hruban, MD, PhD

University of North Carolina, Chapel Hill  
$250,000  
David Ornstein, MD  
Terry Van Dyke, PhD

University of Pennsylvania  
$400,000  
Mark L. Greene, MD, PhD  
Wistar Institute  
George C. Prendergast, PhD

University of Toronto (Canada)  
$350,000  
Sunnybrook Health Science Center  
Shoukut Dedhar, PhD  
Robert S. Kerbel, PhD

University of Utah, Health Sciences Center  
$100,000  
Arthur R. Brothman, PhD

University of Virginia  
$4,150,000  
John M. Chirgwin, PhD  
Leland W.K. Chung, PhD  
Thomas A. Gardner, MD  
Theresa Guise, MD  
Deborah Lamigian, PhD  
Charles E. Myers, Jr., MD  
J. Thomas Parsons, PhD  
Fraydoon Rastinejad, PhD  
Mitchell H. Sokoloff, MD  
Michael J. Weber, PhD

Virginia Commonwealth University  
$14,728,213  
Health Science Center at Richmond  
Paul L. Ackermann, MD  
Mark A. Hruban, MD, PhD

Veteran’s Administration  
$8,745  
Patricia Cornett, MD

Weaver University  
$300,000  
Craig M. Crews, PhD  
Alan Garen, PhD

Wistar Institute  
$4,164,580  
David A. Boothman, PhD  
Wade Bushman, MD, PhD  
Chawnsang Chang, PhD  
David F. Jarrard, MD  
Douglas G. McNeel, MD, PhD  
George Wilding, PhD  
Donald T. Witiak, PhD

Wolfgang Pauli Institute  
(Israel)  
$100,000  
Avri Ben-Ze’ev, PhD  
Hadasa Degani, PhD  
Zelig Eshhar, PhD  
Benjamin Geiger, PhD  
Yitzhak Koch, PhD  
Rony Seger, PhD  
Yechiel Shai, PhD  
Yosef Shaul, PhD  
David Wallach, PhD  
Yosef Yarden, PhD  
Yehiel Zick, PhD

Awardees were performing research at the listed institution at the time funds were granted.
The Prostate Cancer Foundation’s Therapy Consortium supports clinical trial infrastructure at eight leading medical institutions. The following clinical investigators that comprise the Therapy Consortium are among the most respected prostate cancer researchers in the United States:

**Cedars–Sinai Medical Center**
- David B. Agus, MD
  - Research Director, Louis Warschaw Prostate Cancer Center

**Dana–Farber Cancer Institute**
- Philip Kantoff, MD
  - Director, The Lank Center for Genitourinary Oncology; Chief, Division of Solid Tumor Oncology

**MD Anderson Cancer Center, University of Texas**
- Christopher J. Logothetis, MD
  - Chair and Professor, Genitourinary Medical Oncology

**Memorial Sloan–Kettering Cancer Center**
- Howard I. Scher, MD
  - Chief, Genitourinary Oncology Service; D. Wayne Cullenway Chair in Urologic Oncology

**The Johns Hopkins University, Sidney Kimmel Cancer Center**
- Mario A. Eisenberger, MD
  - R. Dale Hughes Professorship in Oncology; Professor of Urology

**University of California, San Francisco Comprehensive Cancer Center**
- Eric J. Small, MD
  - Professor of Medicine and Urology; Director of Urologic Oncology Research

**University of Michigan Medical Center**
- Kenneth J. Pienta, MD
  - Professor of Internal Medicine and Urology; Co-Director of the Urologic/Prostate Oncology Research Program

**University of Wisconsin Comprehensive Cancer Center**
- Maha Hussain, MD
  - Professor of Internal Medicine and Urology

**University of California, San Francisco Comprehensive Cancer Center**
- George Wilding, MD
  - Director, Comprehensive Cancer Center; Assistant Dean for Oncology; Anderson Professor of Medicine
The dedication of the Prostate Cancer Foundation, its Board of Directors and its staff members has enabled hundreds of investigators around the world to work tirelessly to find better treatments and a cure for recurrent prostate cancer.

### Presidential Board

**Jimmy Carter**

**George H.W. Bush**

**Bill Clinton**

### Board of Directors

**Mike Milken**

Founder and Chairman
Prostate Cancer Foundation

**Charles F. Baird, Jr.**

Managing Partner
North Castle Partners

**James Blair**

General Partner
Domain Associates

**S. Ward (Trip) Casscells III, MD**

John Edward Tyson Distinguished Professor of Medicine and Vice President of Biotechnology
University of Texas HSC, Houston

**David Ederer**

Chairman
Ederer Investment Company

**David Epstein**

**R. Christian B. Evensen**

**The Reverend Rosey Grier**

The Milken Family Foundation

**Stuart Holden, MD**

Director, Louis Warschaw Prostate Cancer Center, and Warschaw, Robertson, Law Families Chair in Prostate Cancer
Cedars-Sinai Medical Center
Medical Director
Prostate Cancer Foundation

**Arthur Kern**

Investor

**David H. Koch**

Executive Vice President
Koch Industries

**The Honorable Earle I. Mack**

Senior Partner
The Mack Company

**Jeffrey A. Marcus**

Managing Director
Crestview Advisors

**Shmuel Meitar**

Director
Aurec Group

**Leslie D. Michelson**

Lori Milken
Vice President
Prostate Cancer Foundation

**Jerry Monkarsh**

Partner
EIM Development

**Henry L. Nordhoff**

Chairman, President and Chief Executive Officer
Gen-Probe Incorporated

**Nelson Pelz**

Chairman and Chief Executive Officer
Triarc Companies, Inc.

**Lynda Resnick**

Vice Chairman
Roll International

**Bert Roberts**

Consultant

**Richard Sandler**

Partner
Maron & Sandler
Executive Vice President
The Milken Family Foundation

**J. Gary Shansby**

Chairman
TSG Consumer Partners, LLC

**Lester H. Smith**

Partner
Smith Interests

**Elaine Wynn**

Director
Wynn Resorts

**Stanley Zax**

Chairman and President
Zenith National Insurance Corp.

### Leadership Team

**Jonathan W. Simons, MD**

Chief Executive Officer and President,
David H. Koch Chair

**Ralph Finerman**

Chief Financial Officer,
Treasurer and Secretary

**Debbie Bohnett**

Chief Operating Officer

**Stuart Holden, MD**

Medical Director

**Howard R. Soule, PhD**

Executive Vice President,
Discovery and Translation

**Gregg S. Britt**

Senior Vice President,
Biopharmaceutical Research and Development

**Karen D. Stone**

Senior Vice President,
Development

**Scott Harvey**

Senior Vice President,
Corporate Alliances

**Helen Hsieh**

Vice President,
Finance and Administration

**Jan Haber**

Vice President,
Events and Donor Relations

**Sarah Z. Evans**

Vice President,
Communications

**Shira Berman**

Vice President,
Scientific Programs
Dear Friend,

You have been a source of vital support for the Prostate Cancer Foundation and we thank you. To beat prostate cancer once and for all, the PCF must leverage the talents and resources of thousands of people and institutions around the world. We cannot do it alone. Your help has made a difference.

Every day, the PCF reaches out to new individuals and organizations to join the fight – and appeals to you to stay in the battle with renewed and continued generosity. We are making progress, but we must not let up.

Since 1993 there has been virtually no important discovery in this battle that the PCF has not funded or facilitated. But without your sustained support, the PCF cannot continue funding the research that is so crucial for ending the death and suffering from prostate cancer. Our new Chief Executive Officer and President, Dr. Jonathan Simons, believes that the treatment of prostate cancer has changed significantly just in the last couple of years and is now poised to change quite radically in the next few years to come. I have renewed hope for seeing greatly accelerated progress in the next five years.

We are confident that the research we funded in 2006 will yield remarkable advances. You have a right to be excited by the work that you and other donors helped fund, and you can be encouraged that dedicated investigators are using your dollars to help combat this devastating disease – and that if we keep the funds coming, we have the potential to see new and even better treatment strategies emerge.

Your generosity is crucial for the more than 2 million men, like me, who are currently battling this disease and the more than 234,000 others who were forced to join the battle in 2006. We’ve got to put this disease out of business...soon.

Your giving is the biggest reason men battling this disease can have hope. Please give them more reason to hope today.

With deep gratitude,

David A. Ederer

David A. Ederer
Audit Committee
Prostate Cancer Foundation Board of Directors
Donation Opportunities

The Prostate Cancer Foundation welcomes gifts of cash, securities, non-cash assets and gifts by Will or Living Trust. We also welcome contributions made in memory, in tribute or in honor of friends or loved ones.

Donations

Please mail your check to:

Prostate Cancer Foundation
1250 Fourth Street
Santa Monica, California 90401

To make an online contribution, please visit our website: www.prostatecancerfoundation.org

To make a credit card donation, call 800.757.CURE (2873).

Memorial or Tribute Gifts

Honor the memory of a loved one or celebrate the accomplishment of a friend or family member by helping others.

Make a memorial or tribute gift and the PCF will send an acknowledgment card to the family or honoree.

Other Gift Suggestions

Assets or property including appreciated stock and real estate.

Bequest – Include a gift to the PCF in your Will.

Name the PCF as the primary or contingent beneficiary on a life insurance policy.

Rollover funds from your IRA as a gift to the PCF and avoid all tax on the rollover (valid through 2007 and applies to those 70½ years and older).

Editors: Shira Berman, Sarah Evans, Katie Lambe

Contributing Editors: Sean Grimes, Donovin Matthews, Shavaun Rigler

Special Thanks: Photos courtesy of Jay Weise (front and back cover, pages 3, 6, 9, 12); Milken Family Foundation (pages 10, 13, 18, 20, 21, 22); Rich Cruse (pages 14, 15); HUGO BOSS (page 16); Giorgio Armani (page 17); Ned Dishman/NBAE (page 17); Golf Digest (page 19); Ling Li (pages 20, 21); Bob Each, David Higger, Sherman Miller, Ed Silhan (page 22)

More Information: www.prostatecancerfoundation.org